Berlex Fellowship Open

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

DUMONT, NJ--The Berlex Oncology Foundation is accepting applications until January 6, 1997, for a 2-year clinical research training program open to academically oriented physicians specializing in oncology. The intent is to encourage careers in clinical cancer research. For more information, contact Svetlana Lisanti, Berlex Oncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; or call 201-385-0006.

DUMONT, NJ--The Berlex Oncology Foundation is accepting applicationsuntil January 6, 1997, for a 2-year clinical research trainingprogram open to academically oriented physicians specializingin oncology. The intent is to encourage careers in clinical cancerresearch. For more information, contact Svetlana Lisanti, BerlexOncology Foundation, 80 W. Madison Ave., Dumont, NJ 07628; orcall 201-385-0006.

Articles in this issue
Routine Office Endometrial Biopsies and Ultrasound Screening Are Not Recommended for Breast Cancer Patients Receiving Tamoxifen
AHCPR to Fund Analysis of the Impact of Managed Care's Growth
Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women
ASTRO Honors Two Members With Gold Medal and Bestows Honorary Memberships on Two
Friends of Cancer Research Campaign
Four Cancer Chemoprevention Trials Seek Subjects
Overall US Cancer Mortality Rate Falls for the First Time
Four Scenarios Describe Impact of Cancer Research in 2015
New Edition of NABCO Breast Cancer Resource List Is Now Available
Changes in Congressional Committee Chairmen Could Impact Oncologists
Growth Factor in Elderly ALL Patients Improves Outcome
Human Genetic Map Goes On-Line
Study to Explore Smoking Cessation After a Cancer Diagnosis
Novantrone Gets FDA Nod for Use in Advanced Prostate Cancer
New Cancer Programs, Office of Cancer Survivorship Announced
Recent Videos
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma

Caroline Seymour
November 5th 2025
Article

The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type

Roman Fabbricatore
November 4th 2025
Article

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.